GRI Bio company info

What does GRI Bio do?
GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.
GRI Bio company media
Company Snapshot

Is GRI Bio a public or private company?

key
Ownership
Public

How many people does GRI Bio employ?

people
Employees
4

What sector is GRI Bio in?

pie chart
Sector
Health Care

Where is the head office for GRI Bio?

location pin
Head Office
La Jolla, United States

What year was GRI Bio founded?

founded flag
Year Founded
2009
What does GRI Bio specialise in?
/Real Estate Investments /Global Diversification /Asset Management /Equity Portfolio /Fund Management /Investment Research

What are the products and/or services of GRI Bio?

Overview of GRI Bio offerings
Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.

Who is in the executive team of GRI Bio?

GRI Bio leadership team
  • Dr. W. Marc Hertz Ph.D.
    Dr. W. Marc Hertz Ph.D.
    Co-Founder, CEO, President & Director
  • Ms. Leanne M. Kelly
    Ms. Leanne M. Kelly
    CFO & Corporate Secretary
  • Dr. Vipin  Kumar Chaturvedi Ph.D.
    Dr. Vipin Kumar Chaturvedi Ph.D.
    Co-Founder & Chief Scientific Officer
  • Dr. Albert  Agro Ph.d.
    Dr. Albert Agro Ph.d.
    Chief Medical Officer